{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T15:11:20Z","timestamp":1795014680286,"version":"4.9.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recently, chimeric antigen receptor-modified (CAR) T cell therapy for hematological malignancies has shown clinical efficacy. Hundreds of clinical trials have been registered and lots of studies have shown hematologic toxic effects were very common. The main purpose of this review is to systematically analyze hematologic toxicity in hematologic malignancies treated with CAR-T cell therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched databases including PubMed, Web of Science, Embase and Cochrane up to January 2021. For safety analysis of overall hematologic toxicity, the rate of neutrophil, thrombocytopenia and anemia were calculated. Subgroup analysis was performed for age, pathological type, target antigen, co-stimulatory molecule, history of hematopoietic stem cell transplantation (HSCT) and prior therapy lines. The incidence rate of aspartate transferase (AST) increased, alanine transaminase (ALT) increased, serum creatine increased, APTT prolonged and fibrinogen decreased were also calculated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 52 studies involving 2004 patients were included in this meta-analysis. The incidence of any grade neutropenia, thrombocytopenia and anemia was 80% (95% CI: 68\u201389%), 61% (95% CI: 49\u201373%), and 68% (95%CI: 54\u201380%) respectively. The incidences of grade\u2009\u2265\u20093 neutropenia, thrombocytopenia and anemia were 60% (95% CI: 49\u201370%), 33% (95% CI: 27\u201340%), and 32% (95%CI: 25\u201340%) respectively. According to subgroup analysis and the corresponding Z test, hematological toxicity was more frequent in younger patients, in patients with \u22654 median lines of prior therapy and in anti-CD19 cases. The subgroup analysis of CD19 CAR-T cell constructs showed that 41BB resulted in less hematological toxicity than CD28.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>CAR-T cell therapy has dramatical efficacy in hematological malignancies, but the relevant adverse effects remain its obstacle. The most common \u22653 grade side effect is hematological toxicity, and some cases die from infections or severe hemorrhage in early period. In long-term follow-up, hematological toxicity is less life-threatening generally and most suffered patients recover to adequate levels after 3\u2009months. To prevent life-threatening infections or bleeding events, clinicians should pay attention to intervention of hematological toxicity in the early process of CAR-T cell therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-09102-x","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T10:03:50Z","timestamp":1643018630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Wenjing","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenggong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7941-2443","authenticated-orcid":false,"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"issue":"17","key":"9102_CR1","doi-asserted-by":"publisher","first-page":"6091","DOI":"10.3390\/ijms21176091","volume":"21","author":"P Auberger","year":"2020","unstructured":"Auberger P, Tamburini-Bonnefoy J, Puissant A. Drug Resistance in Hematological Malignancies. Int J Mol Sci. 2020;21(17):6091.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"9102_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nrc3565","volume":"13","author":"MH Kershaw","year":"2013","unstructured":"Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer. 2013;13(8):525\u201341.","journal-title":"Nat Rev Cancer"},{"key":"9102_CR3","doi-asserted-by":"crossref","unstructured":"Haslauer T, Greil R, Zaborsky N, Geisberger R. CAR T-cell therapy in hematological malignancies. Int J Mol Sci. 2021;22(16):8996.","DOI":"10.3390\/ijms22168996"},{"key":"9102_CR4","doi-asserted-by":"crossref","unstructured":"Juluri KR, Wu V, Voutsinas JM, Hou J, Hirayama AV, Mullane E, et al. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv. 2021:bloodadvances.2020004142.","DOI":"10.1182\/bloodadvances.2020004142"},{"key":"9102_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.544754","volume":"11","author":"X Xiang","year":"2020","unstructured":"Xiang X, He Q, Ou Y, Wang W, Wu Y. Efficacy and safety of CAR-modified T cell therapy in patients with relapsed or refractory multiple myeloma: a meta-analysis of prospective clinical trials. Front Pharmacol. 2020;11:544754.","journal-title":"Front Pharmacol"},{"key":"9102_CR6","unstructured":"PRISMA checklist [http:\/\/www.prisma-statement.org\/PRISMAStatement\/Checklist.aspx]."},{"issue":"2","key":"9102_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60\u20133.","journal-title":"BMJ Evid Based Med"},{"key":"9102_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.omto.2019.08.002","volume":"15","author":"Z Ying","year":"2019","unstructured":"Ying Z, He T, Wang X, Zheng W, Lin N, Tu M, et al. Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin's lymphoma. Mol Ther-Oncol. 2019;15:60\u20138.","journal-title":"Mol Ther-Oncol"},{"issue":"23","key":"9102_CR9","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.1158\/1078-0432.CCR-19-0101","volume":"25","author":"Z-X Yan","year":"2019","unstructured":"Yan Z-X, Li L, Wang W, OuYang B-S, Cheng S, Wang L, et al. Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin's lymphoma. Clin Cancer Res. 2019;25(23):6995\u20137003.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"9102_CR10","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1002\/cam4.3259","volume":"9","author":"W Sang","year":"2020","unstructured":"Sang W, Shi M, Yang J, Cao J, Xu L, Yan D, et al. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer Med. 2020;9(16):5827\u201338.","journal-title":"Cancer Med"},{"issue":"14","key":"9102_CR11","first-page":"1632","volume":"136","author":"C Tong","year":"2020","unstructured":"Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, et al. Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma. Blood. 2020;136(14):1632\u201344.","journal-title":"Blood"},{"issue":"19","key":"9102_CR12","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc Natl Acad Sci U S A. 2019;116(19):9543\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"9102_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"WH Zhao","year":"2018","unstructured":"Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11(1):141.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"9102_CR14","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","volume":"26","author":"NN Shah","year":"2020","unstructured":"Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020;26(10):1569\u201375.","journal-title":"Nat Med"},{"issue":"2","key":"9102_CR15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/ijlh.13375","volume":"43","author":"Y Wang","year":"2021","unstructured":"Wang Y, Li H, Song X, Qi K, Cheng H, Cao J, et al. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients. Int J Lab Hematol. 2021;43(2):250\u20138.","journal-title":"Int J Lab Hematol."},{"issue":"10","key":"9102_CR16","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","volume":"54","author":"S Fried","year":"2019","unstructured":"Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019;54(10):1643\u201350.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"9102_CR17","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.1038\/s41467-020-19774-x","volume":"11","author":"F An","year":"2020","unstructured":"An F, Wang H, Liu Z, Wu F, Zhang J, Tao Q, et al. Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia. Nat Commun. 2020;11(1):5928.","journal-title":"Nat Commun"},{"issue":"32","key":"9102_CR18","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020;38(32):3794\u2013804.","journal-title":"J Clin Oncol"},{"issue":"18","key":"9102_CR19","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726\u201337.","journal-title":"N Engl J Med"},{"issue":"10254","key":"9102_CR20","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet (London, England). 2020;396(10254):839\u201352.","journal-title":"Lancet (London, England)"},{"issue":"14","key":"9102_CR21","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"issue":"6","key":"9102_CR22","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129(6):2210\u201321.","journal-title":"J Clin Invest"},{"issue":"9","key":"9102_CR23","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1007\/s10147-020-01699-6","volume":"25","author":"H Goto","year":"2020","unstructured":"Goto H, Makita S, Kato K, Tokushige K, Fujita T, Akashi K, et al. Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed\/refractory diffuse large B-cell lymphoma. Int J Clin Oncol. 2020;25(9):1736\u201343.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"9102_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"9","key":"9102_CR25","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25(9):1408\u201314.","journal-title":"Nat Med"},{"issue":"5","key":"9102_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"10","key":"9102_CR27","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.3324\/haematol.2020.254045","volume":"106","author":"P Strati","year":"2021","unstructured":"Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, et al. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2021;106(10):2667\u201372.","journal-title":"Haematologica."},{"issue":"1","key":"9102_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"1","key":"9102_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20\u20138.","journal-title":"Nat Med"},{"issue":"13","key":"9102_CR30","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128(13):1688\u2013700.","journal-title":"Blood"},{"issue":"24","key":"9102_CR31","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","volume":"24","author":"G Enblad","year":"2018","unstructured":"Enblad G, Karlsson H, Gammelgard G, Wenthe J, Lovgren T, Amini RM, et al. A phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia. Clin Cancer Res. 2018;24(24):6185\u201394.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"9102_CR32","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak \u00d6, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545\u201354.","journal-title":"N Engl J Med"},{"issue":"25","key":"9102_CR33","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322\u201331.","journal-title":"Blood"},{"issue":"26","key":"9102_CR34","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1182\/blood.2019001641","volume":"134","author":"KJ Curran","year":"2019","unstructured":"Curran KJ, Margossian SP, Kernan NA, Silverman LB, Williams DA, Shukla N, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL. Blood. 2019;134(26):2361\u20138.","journal-title":"Blood"},{"issue":"12","key":"9102_CR35","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","volume":"26","author":"CA Ramos","year":"2018","unstructured":"Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, et al. In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin's lymphomas. Mol Ther. 2018;26(12):2727\u201337.","journal-title":"Mol Ther"},{"key":"9102_CR36","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1038\/sigtrans.2016.2","volume":"1","author":"WY Zhang","year":"2016","unstructured":"Zhang WY, Wang Y, Guo YL, Dai HR, Yang QM, Zhang YJ, et al. Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report. Signal Transduct Target Ther. 2016;1:16002.","journal-title":"Signal Transduct Target Ther"},{"issue":"9967","key":"9102_CR37","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u201328.","journal-title":"Lancet (London, England)"},{"issue":"8","key":"9102_CR38","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/j.ymthe.2018.05.018","volume":"26","author":"MB Geyer","year":"2018","unstructured":"Geyer MB, Rivi\u00e8re I, S\u00e9n\u00e9chal B, Wang X, Wang Y, Purdon TJ, et al. Autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy. Mol Ther. 2018;26(8):1896\u2013905.","journal-title":"Mol Ther"},{"key":"9102_CR39","doi-asserted-by":"crossref","unstructured":"Geyer MB, Rivi\u00e8re I, S\u00e9n\u00e9chal B, Wang X, Wang Y, Purdon TJ, et al. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed\/refractory CLL. JCI insight. 2019;5(9):e122627.","DOI":"10.1172\/jci.insight.122627"},{"issue":"11","key":"9102_CR40","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ajh.25951","volume":"95","author":"P Sesques","year":"2020","unstructured":"Sesques P, Ferrant E, Safar V, Wallet F, Tordo J, Dhomps A, et al. Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center. Am J Hematol. 2020;95(11):1324\u201333.","journal-title":"Am J Hematol"},{"issue":"1","key":"9102_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood.2019000017","volume":"135","author":"N Wang","year":"2020","unstructured":"Wang N, Hu X, Cao W, Li C, Xiao Y, Cao Y, et al. Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies. Blood. 2020;135(1):17\u201327.","journal-title":"Blood"},{"key":"9102_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.564099","volume":"11","author":"X Zhou","year":"2020","unstructured":"Zhou X, Tu S, Wang C, Huang R, Deng L, Song C, et al. Phase I trial of fourth-generation anti-CD19 chimeric antigen receptor T cells against relapsed or refractory B cell non-Hodgkin lymphomas. Front Immunol. 2020;11:564099.","journal-title":"Front Immunol"},{"issue":"2","key":"9102_CR43","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bjh.16623","volume":"191","author":"J Wang","year":"2020","unstructured":"Wang J, Mou N, Yang Z, Li Q, Jiang Y, Meng J, et al. Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory\/relapsed B acute lymphoblastic leukaemia. Br J Haematol. 2020;191(2):212\u201322.","journal-title":"Br J Haematol."},{"issue":"10","key":"9102_CR44","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","volume":"6","author":"Z Yan","year":"2019","unstructured":"Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019;6(10):e521\u20139.","journal-title":"Lancet Haematol"},{"key":"9102_CR45","unstructured":"Bao F, Hu K, Wan W, Tian L, Jing HM. Efficacy of anti-CD19 CAR-T cell therapy in 10 refractory recurrent B cell malignancies. Zhonghua Xue Ye Xue Za Zhi. 2018;39(6):454\u20139. Chinese."},{"issue":"15","key":"9102_CR46","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","volume":"4","author":"T Jain","year":"2020","unstructured":"Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4(15):3776\u201387.","journal-title":"Blood Adv"},{"key":"9102_CR47","doi-asserted-by":"crossref","unstructured":"Popat R, Zweegman S, Cavet J, Yong K, Lee L, Faulkner J, et al. Phase 1 first-in-human study of AUTO2, the first chimeric antigen receptor (CAR) T cell targeting april for patients with relapsed\/refractory multiple myeloma (RRMM). Blood.\u00a02019;134(Supplement 1):3112.","DOI":"10.1182\/blood-2019-126689"},{"issue":"Supplement 1","key":"9102_CR48","first-page":"417","volume":"4","author":"SZ Usmani","year":"2020","unstructured":"Usmani SZ, Madduri D, Berdeja JG, Singh I, Zudaire E, Yeh TM, et al. Treatment of relapsed\/refractory multiple myeloma with JNJ-4528, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy: update of phase 1b results from cartitude-1. HemaSphere. 2020;4(Supplement 1):417\u20138.","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"9102_CR49","first-page":"418","volume":"4","author":"S Mailankody","year":"2020","unstructured":"Mailankody S, Jakubowiak A, Htut M, Costa L, Lee K, Ganguly S, et al. Orvacabtagene autoleucel (Orva-cel), a B-cell maturation antigen-directed car t cell therapy for patients with relapsed\/refractory multiple myeloma: update of the phase 1\/2 evolve study. HemaSphere. 2020;4(Supplement 1):418.","journal-title":"HemaSphere"},{"key":"9102_CR50","doi-asserted-by":"crossref","unstructured":"Hu J, Yang T, Yang X, Xian N, Chen Y, Jiang P, et al. Repeat infusion of CD19-specific chimeric antigen receptor T-cell could improve the efficacy with consistent safety in relapsed\/refractory diffuse large B-cell lymphoma. Blood.\u00a02018;132(Supplement 1):5385.","DOI":"10.1182\/blood-2018-99-119100"},{"key":"9102_CR51","doi-asserted-by":"crossref","unstructured":"Amrolia PJ, Wynn R, Hough R, Vora A, Bonney D, Veys P, et al. Simultaneous targeting of CD19 and CD22: phase I study of AUTO3, a Bicistronic chimeric antigen receptor (CAR) T-cell therapy, in pediatric patients with relapsed\/refractory B-cell acute lymphoblastic leukemia (r\/r B-ALL): Amelia study. Blood.\u00a02018;132(Supplement 1):279.","DOI":"10.1182\/blood-2018-99-118616"},{"key":"9102_CR52","doi-asserted-by":"crossref","unstructured":"Ardeshna K, Marzolini MAV, Osborne W, Al-Hajj M, Thomas S, Faulkner J, et al. Study of AUTO3, the first Bicistronic chimeric antigen receptor (CAR) targeting CD19 and CD22, followed by anti-PD1 consolidation in patients with relapsed\/refractory (r\/r) diffuse large B cell lymphoma (DLBCL): Alexander study. Blood.\u00a02018;132(Supplement 1):1679.","DOI":"10.1182\/blood-2018-99-119197"},{"key":"9102_CR53","doi-asserted-by":"crossref","unstructured":"Yan L, Yan Z, Shang J, Shi X, Jin S, Kang L, et al. Sequential CD19-and Bcma-specific chimeric antigen receptor T cell treatment for RRMM: report from a single center study. Blood.\u00a02019;134(Supplement_1):578.","DOI":"10.1182\/blood-2019-129740"},{"key":"9102_CR54","doi-asserted-by":"crossref","unstructured":"Wierda WG, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, et al. Updated phase 1 results of Zuma-3: Kte-C19, an anti-CD19 chimeric antigen receptor T cell therapy, in adult patients with relapsed\/refractory acute lymphoblastic leukemia. Blood.\u00a02018;132(Supplement 1):897.","DOI":"10.1182\/blood-2018-99-111531"},{"issue":"Supplement 2","key":"9102_CR55","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/hon.114_2630","volume":"37","author":"MS Topp","year":"2019","unstructured":"Topp MS, Van Meerten T, Wermke M, Lugtenburg PJ, Minnema MC, Song KW, et al. Preliminary results of earlier steroid usewith axicabtagene ciloleucel (AXI-CEL) in patients with relapsed\/refractory large b cell lymphoma. Hematol Oncol. 2019;37(Supplement 2):305.","journal-title":"Hematol Oncol"},{"key":"9102_CR56","doi-asserted-by":"crossref","unstructured":"Jiang S, Jin J, Hao S, Yang M, Chen L, Ruan H, et al. Low dose of human scFv-derived BCMA-targeted CAR-T cells achieved fast response and high complete remission in patients with relapsed\/refractory multiple myeloma. Blood.\u00a02018;132(Supplement 1):960.","DOI":"10.1182\/blood-2018-99-113220"},{"key":"9102_CR57","doi-asserted-by":"crossref","unstructured":"Dourthe ME, Rabian F, Yakouben K, Cabannes A, Chevillon F, Chaillou D, et al. Safety and efficacy of tisagenlecleucel (CTL019) in B-cell acute lymphoblastic leukemia in children, adolescents and young adults: the French experience. Blood.\u00a02019;134(Supplement 1):3876.","DOI":"10.1182\/blood-2019-131123"},{"issue":"Supplement 1","key":"9102_CR58","first-page":"40","volume":"136","author":"C Jacobson","year":"2020","unstructured":"Jacobson C, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Primary analysis of Zuma-5: a phase 2 study of Axicabtagene Ciloleucel (Axi-Cel) in patients with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL). Blood. 2020;136(Supplement 1):40\u20131.","journal-title":"Blood"},{"issue":"S1","key":"9102_CR59","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/01.HS9.0000562152.07779.48","volume":"3","author":"AS Wayne","year":"2019","unstructured":"Wayne AS, Huynh V, Hijiya N, Rouce R, Brown PA, Krueger J, et al. PS962 phase 1 results of ZUMA-4: KTE-X19, an anti-CD19 chimeric antigen receptor t cell therapy, in pediatric and adolescent patients with relapsed\/refractory b cell acute lymphoblastic leukemia. HemaSphere. 2019;3(S1):433.","journal-title":"HemaSphere"},{"issue":"16","key":"9102_CR60","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"key":"9102_CR61","doi-asserted-by":"crossref","unstructured":"Yan Z, Wang W, Zheng Z, Hao M, Yang S, Li J, et al. Efficacy and Safety of JWCAR029 in adult patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Blood.\u00a02018;132(Supplement 1):4187.","DOI":"10.1182\/blood-2018-99-115769"},{"key":"9102_CR62","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","volume":"18","author":"X Zhao","year":"2020","unstructured":"Zhao X, Yang J, Zhang X, Lu X-A, Xiong M, Zhang J, et al. Efficacy and safety of CD28-or 4-1BB-based CD19 CAR-T cells in B cell acute lymphoblastic leukemia. Molecular Therapy-Oncolytics. 2020;18:272\u201381.","journal-title":"Molecular Therapy-Oncolytics"},{"issue":"1","key":"9102_CR63","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/CM9.0000000000000568","volume":"133","author":"XH Zheng","year":"2020","unstructured":"Zheng XH, Zhang XY, Dong QQ, Chen F, Yang SB, Li WB. Efficacy and safety of chimeric antigen receptor-T cells in the treatment of B cell lymphoma: a systematic review and meta-analysis. Chin Med J. 2020;133(1):74\u201385.","journal-title":"Chin Med J"},{"issue":"4","key":"9102_CR64","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1182\/bloodadvances.2020004017","volume":"5","author":"GR Mohyuddin","year":"2021","unstructured":"Mohyuddin GR, Rooney A, Balmaceda N, Aziz M, Sborov DW, McClune B, et al. Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. Blood advances. 2021;5(4):1097\u2013101.","journal-title":"Blood advances"},{"issue":"11","key":"9102_CR65","doi-asserted-by":"publisher","first-page":"e816","DOI":"10.1016\/S2352-3026(20)30277-5","volume":"7","author":"T Anagnostou","year":"2020","unstructured":"Anagnostou T, Riaz IB, Hashmi SK, Murad MH, Kenderian SS. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. The Lancet Haematology. 2020;7(11):e816\u201326.","journal-title":"The Lancet Haematology"},{"issue":"26","key":"9102_CR66","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"10","key":"9102_CR67","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","volume":"25","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T, Yang JC, Sherry RM, Feldman SA, et al. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol Ther. 2017;25(10):2245\u201353.","journal-title":"Mol Ther"},{"issue":"1","key":"9102_CR68","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","volume":"26","author":"A Cordeiro","year":"2020","unstructured":"Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biology of Blood and Marrow Transplantation. 2020;26(1):26\u201333.","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"32","key":"9102_CR69","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.20.01467","volume":"38","author":"KM Cappell","year":"2020","unstructured":"Cappell KM, Sherry RM, Yang JC, Goff SL, Vanasse DA, McIntyre L, et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J Clin Oncol. 2020;38(32):3805\u201315.","journal-title":"J Clin Oncol"},{"key":"9102_CR70","doi-asserted-by":"crossref","unstructured":"Warrier VU, Makandar AI, Garg M, Sethi G, Kant R, Pal JK, et al. Engineering anti-cancer nanovaccine based on antigen cross-presentation. Biosci Rep. 2019;39(10):BSR20193220.","DOI":"10.1042\/BSR20193220"},{"issue":"13 Suppl","key":"9102_CR71","first-page":"S243","volume":"27","author":"LW Buie","year":"2021","unstructured":"Buie LW. Balancing the CAR T: perspectives on efficacy and safety of CAR T-cell therapy in hematologic malignancies. Am J Manag Care. 2021;27(13 Suppl):S243\u201352.","journal-title":"Am J Manag Care"},{"issue":"1","key":"9102_CR72","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, M\u00fcller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34\u201348.","journal-title":"Ann Oncol"},{"issue":"8","key":"9102_CR73","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00109-020-01944-5","volume":"98","author":"A Kirtonia","year":"2020","unstructured":"Kirtonia A, Pandya G, Sethi G, Pandey AK, Das BC, Garg M. A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia. J Mol Med (Berl). 2020;98(8):1069\u201391.","journal-title":"J Mol Med (Berl)"},{"issue":"Suppl 4","key":"9102_CR74","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000746","volume":"4","author":"L Y\u00e1\u00f1ez","year":"2020","unstructured":"Y\u00e1\u00f1ez L, Alarc\u00f3n A, S\u00e1nchez-Escamilla M, Perales MA. How I treat adverse effects of CAR-T cell therapy. ESMO Open. 2020;4(Suppl 4):e000746.","journal-title":"ESMO Open"},{"issue":"19","key":"9102_CR75","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood.2019002936","volume":"135","author":"J Gauthier","year":"2020","unstructured":"Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135(19):1650\u201360.","journal-title":"Blood"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09102-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-09102-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09102-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T18:06:14Z","timestamp":1666721174000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-09102-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9102"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-09102-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"2 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}